Reuters logo
BRIEF-Asterias announces two significant developments for spinal cord injury program
October 2, 2017 / 11:20 AM / in 2 months

BRIEF-Asterias announces two significant developments for spinal cord injury program

Oct 2 (Reuters) - Asterias Biotherapeutics Inc

* Asterias Biotherapeutics - announced new 12-month data from first efficacy cohort in ongoing phase 1/2a SCiStar study to evaluate safety, efficacy of AST-OPC1

* Asterias Biotherapeutics - new data showed 67 percent of cohort 2 subjects in study have recovered two or more motor levels on at least one side through 12 months

* Asterias Biotherapeutics - FDA granted request for AST-OPC1 to be designated a Regenerative Medicine Advanced Therapy under 21(st) Century Cures Act Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below